• Perspectives on Seborrheic Dermatitis: Looking Back to Move Ahead
• Evaluation of a Nonsteroidal Topical Cream in a Guinea Pig Model of Malassezia Furfur Infection
• An Open-Label, Single-Center Pilot Study to Determine the Antifungal Activity of a New Nonsteroidal Cream (Promiseb Topical Cream) After 7 Days of Use in Healthy Volunteers
• An Investigator-Blind, Randomized, 4-Week, Parallel-Group, Multicenter Pilot Study to Compare the Safety and Efficacy of a Nonsteroidal Cream (Promiseb Topical Cream) and Desonide Cream 0.05% in the Twice-Daily Treatment of Mild to Moderate Seborrheic Dermatitis of the Face
Guest Editor: James Q. Del Rosso, DO
Las Vegas Skin and Cancer Clinics
Las Vegas, NV
Dr. Del Rosso is a consultant to, and serves as a speaker for Allergan Inc., Amgen Inc., Arcutis Pharmaceuticals, Coria Laboratories Ltd., Galderma Laboratories, L.P., Graceway Pharmaceuticals, LLC, Intendis, Inc., Medicis Pharmaceutical Corporation, Onset Therapeutics, OrthoNeutrogena, PharmaDerm, Quinnova Pharmaceuticals, Inc., Ranbaxy Laboratories, Ltd., Stiefel Laboratories, Inc., Triax Pharmaceuticals, LLC, Unilever and Warner Chilcott.
Boni E. Elewski, MD
Vice-Chair for Clinical Affairs
Professor of Dermatology
University of Alabama at Birmingham
Department of Dermatology
San Diego, California
Dr. Elewski has received clinical grant funding from and is a consultant to Johnson & Johnson and Stiefel Laboratories, Inc.
Leon H. Kircik, MD, FAAD
Associate Clinical Professor of Dermatology
Indiana University Medical Center
Dr. Kircik is a consultant, an investigator, and serves as a speaker for Promius.
Mr. Vijendra Nalamothu
Senior Director, Research & Development
Promius Pharma, LLC
Mr. Nalamothu is an employee of Promius Pharma, LLC.
Ann L. O'Leary, PhD
Ricerca Biosciences, LLC
Dr. O'Leary has nothing to disclose.
Copyright © 2009 by Elsevier Inc.